

**When getting back
to the clinic becomes
a little difficult**

Warticon is a highly effective treatment for male genital warts situated in the preputial space.^{1,2,3}

It can be applied by the patient, in his own home, twice daily for three days, following an initial visit to a GUM clinic.


Warticon therefore relieves the patient, and the clinic, of the time and effort of regular attendance for treatment.¹

Warticon[®]
podophyllotoxin 0.5% w/v

**Simple enough for self-application in
male genital warts**

 **Perstorp Pharma**

Further information is available from: Perstorp Pharma Ltd, Intec 2, Wade Road, Basingstoke, Hants RG24 0NE Tel:(0256) 477868

 and Warticon are registered trademarks

ABBREVIATED PRESCRIBING INFORMATION

Warticon: Podophyllotoxin 0.5% w/v. **Presentation:** An acidic ethanolic solution of 0.5% w/v podophyllotoxin. **Uses:** For the treatment of penile warts (condylomata acuminata), located in the preputial space. **Dosage and Administration:** The affected area should be washed and dried prior to application. Using the applicator provided, the warts should be painted twice daily for 3 days. The treated area should be allowed to dry. Treatment may be repeated after 7 days. Maximum single dose of 30 loops per application for at-home treatment (50 loops under medical supervision). Where lesions are greater in area than 4cm², it is recommended that treatment takes place under the direct supervision of medical staff. **Contraindications, Warnings, etc:** Open wounds, hypersensitivity to podophyllotoxin. In the event of the preparation entering the eye, the eye should be thoroughly bathed in water. **Side effects:** Local irritation may occur. In the majority of cases the reactions are mild. **Overdosage:** No overdoses have been reported. No specific antidote is known. Following accidental spillage, wash the affected area with soap and water. In the event of accidental ingestion give emetic or stomach washout. Treatment should be symptomatic. **Pharmaceutical Precautions:** Store at room temperature. **Package Quantities:** Bottle containing Warticon 3ml. Plastic applicators are also enclosed in each pack. Each loop will carry 5µl Warticon Solution. **Legal Category:** POM. **Basic NHS Cost:** 3 ml £16.00. **Product Licence Number:** PL 3863/0007.

REFERENCES

1. Pickering RW. Br J Sex Med 1989; 16: 320-324.
2. Lassus A, et al. Eur J Sex Trans Dis 1984; 2: 31-33.
3. von Krogh G. In Derm in Five Continents. Proceedings of the XVII World Congress of Dermatology 1987: 317-326.

Journal of Medical Screening

Editor: **Nicholas Wald**

Wolfson Institute of Preventive Medicine

Associate Editors include:

J Chamberlain (UK), N E Day (UK), J E Haddow (US), M Law (UK)

Journal of Medical Screening is a new quarterly journal to be launched in January 1994 by the BMJ Publishing Group to cover all aspects of medical screening and advance the science of the discipline. The journal aims to bring together specialist groups conducting screening research and establish a liaison with health authorities and policy developers. The philosophy of the journal is that screening should be about the prevention of disability and disease, not simply the early detection of disease as an end in itself.

SUBMISSION

Papers should be submitted to:
Professor Nicholas Wald
Wolfson Institute of Preventive Medicine
Medical College of St. Bartholomew's Hospital
Charterhouse Square, London EC1M 6BQ, United Kingdom
Tel: 44 71 982 6269 Fax: 44 71 982 6272

Instructions to Authors may be obtained by returning the form below

The Journal Aims to Cover:

Principles and theory of medical screening

Research into screening methodology

Development of new screening tests and their quantitative evaluation

All aspects of public health as they relate to screening, including epidemiology, randomised trials, quantitative observational studies, demonstration projects and economic evaluations

Ethical and psychological issues

Management issues

Policy and strategy



JOURNAL OF MEDICAL SCREENING

PUBLICATION: Quarterly

ISSN: 0969-1413

Please tick

- Please send me more information
 Please send me *Instructions to Authors*
 Please send me a sample copy

Order Form

Name (*capitals*) _____

Specialty/Position _____

Address _____

_____ Date _____

Return forms to: Rachel Armitage, BMJ Publishing Group, BMA House, Tavistock Square, London, WC1H 9JR. Tel: 071-383 6674

Your patients rely on you...

To provide the most accurate diagnosis and effective treatment, you need the most current, comprehensive information available. This journal will help you deal with the panic...anxiety...and often misinformation of the patients coming to you concerning sexually transmitted disease.

Identify those at risk

Diagnose infected patients


Provide facts and advice for those who feel threatened

Treat your patients with the most effective therapies

Your source is *Sexually Transmitted Diseases*


Published bi-monthly, *Sexually Transmitted Diseases* brings you the most up-to-date information on sexually transmitted diseases and related topics. Original articles keep you abreast of the latest advances in diagnosis and treatment, patient education, public health issues, etiology and pathology. Newly identified syndromes and disease entities are covered in each issue, along with notes from the CDC and NIH, case reports, and AVDA News.

Subscribe to the resource you can rely on for the latest, most authoritative information on STDs!



No-Risk Guarantee!

If you're not completely satisfied, you may cancel your subscription at any time and receive a refund for all unmailed issues.



Call us today TOLL FREE
1-800-638-3030 (U.S. except AK)
or FAX your order 301-824-7390.

Published bi-monthly
Annual subscription rates:
Individual \$100.00 (U.S.) - \$115.00 (Other countries)
Institution \$145.00 (U.S.) - \$180.00 (Other countries)

Published by

J. B. Lippincott

A Wolters Kluwer Company



Journals Division
J. B. Lippincott
227 East Washington Square
Philadelphia, PA 19106-3780
USA


...and you can rely on *Sexually Transmitted Diseases*

Journal of the American Venereal Disease Association
Julius Schachter, PhD, Editor

Prescribing information *Indications and dosage:* Systemic candidiasis: 400mg on the first day followed by 200-400mg once daily. Cryptococcosis, including meningitis: 400mg on the first day followed by 200-400mg once daily. Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with AIDS: 100-200mg daily. Oropharyngeal candidiasis: 50-100mg once daily for 7-14 days or longer in immunocompromised patients. Other mucosal candidal infections: 50-100mg once daily for 14-30 days. Vaginal candidiasis: single 150mg dose. Prevention of fungal infections in neutropenic patients following cytotoxic chemotherapy or radiotherapy: 50-100mg once daily whilst patients are predisposed to such infections. Use in the elderly - as above except for those renally impaired - see data sheet. Use in children - not recommended. *Administration:* Diflucan may be administered either orally or by intravenous infusion at a rate of approximately 5-10ml/min. The dosages for the two routes are equivalent. *Contra-indications:* Hypersensitivity to fluconazole or related triazoles, pregnancy and women of childbearing potential unless adequate contraception is employed. *Warnings:* Lactation - not recommended. Renal impairment: dosage reduction may be necessary, see data sheet. *Drug interactions:* Monitor patients on concurrent anticoagulants, oral sulphonylureas, phenytoin or cyclosporin, rifampicin or theophylline. *Side-effects:* Nausea, abdominal discomfort, diarrhoea, flatulence and anaphylaxis. *Package Quantities and Basic NHS cost:* 50mg capsule, calendar pack of 7, £16.61 (PL 57/0289); 200mg capsule, calendar pack of 7, £66.42 (PL 57/0317); 150mg capsule, pack of 1, £7.12 (PL 57/0290); Powder for Oral Suspension, 35ml after reconstitution with water: Bottle of 50mg/5ml, £16.61 (PL 57/0343), Bottle of 200mg/5ml, £66.42 (PL 57/0344); Bottles of 25ml and 100ml containing Diflucan 2mg/ml intravenous infusion - 25ml (50mg) bottle, £7.32; 100ml (200mg) bottle, £29.28 (PL 57/0315). Hospital prices are available on request. *References* 1. Data on file, Pfizer Ltd. 2. Brammer, K.W. (1990), *Haematology and Blood Transfusion*, 33, 546-550. 3. Samonis, G. et al. (1990), *Reviews of Infectious Diseases*, 12(3), S369-S373. 4. Data on file, Pfizer Ltd. 5. Buxton, M.J. et al. (1991), *Journal of Infection*, 23, 17-31. Further information on request. Pfizer Limited, Sandwich, Kent



AWARDED TO CENTRAL RESEARCH DIVISION OF PFIZER LIMITED



It takes a
good antifungal
routine
to break the
vicious cycle
of Candida.

DIFLUCAN* is a highly effective antifungal agent with activity against a wide range of common invasive fungal infections.¹ It should be considered as a first-line treatment in suspected or proven candidal or cryptococcal infections. DIFLUCAN also provides effective prophylactic therapy in neutropenic patients and in patients with solid tumours.^{2,3}

DIFLUCAN has a good safety profile and is well tolerated in both its oral and intravenous forms.⁴ Since DIFLUCAN is generally better tolerated than I.V. amphotericin B, patients require less hospital care and can be treated on an outpatient basis thus facilitating a substantial reduction in costs.⁵

Diflucan* ORAL/I.V. Counters invasive fungal infection.
fluconazole *Trade Mark